Company Overview - Kodiak Sciences is a clinical-stage biotechnology company focused on innovative therapies for retinal diseases [6] - The company has a market capitalization of $1.6 billion and a net income of -$217.34 million [4] - As of February 23, 2026, the share price was $25.91, reflecting a 480% increase over the past year, significantly outperforming the S&P 500's 13% gain [7] Recent Developments - On February 17, 2026, Baker Bros. Advisors LP disclosed the purchase of 2,608,696 shares of Kodiak Sciences, valued at approximately $53.42 million [1][2] - The value of Kodiak Sciences' holdings increased by $273.57 million at the end of the fourth quarter of 2025, accounting for both the additional shares and stock price movement [2] Product Pipeline - Kodiak's lead product candidate, KSI-301, is in Phase IIb/III trials targeting wet age-related macular degeneration and other retinal disorders [8] - The company is also advancing KSI-101 in the PEAK and PINNACLE studies for retinopathy, targeting a segment within the $15 billion anti-VEGF marketplace [9] Financial Performance - In the third quarter, Kodiak Sciences reported R&D spending of $50.5 million and a net loss of $61.5 million [9] - The company had cash reserves of $72 million as of September 30, 2025, prior to a $184 million capital raise in December [9] Investment Implications - Kodiak Sciences represents 3.26% of Baker Bros. Advisors LP's 13F reportable assets under management (AUM) after the recent trade [7] - The company's future performance hinges on the success of its Phase 3 trials, which could position it competitively in the retinal vascular disease market [10]

Core Insights - Ocular Therapeutix will present detailed results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration at the 49th Macula Society Annual Meeting on February 27, 2026 [1][2] - An investor webcast is scheduled for March 2, 2026, to discuss the SOL-1 data presented at the meeting [1][3] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [5] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal diseases, currently in Phase 3 trials for wet AMD and diabetic retinal disease [5] - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [6]

Company Overview - Kodiak Sciences is a biotechnology company focused on developing innovative therapies for retinal diseases, leveraging advanced antibody biopolymer technology to address significant unmet medical needs in ophthalmology [6]. - The company has a pipeline led by KSI-301, which is currently in Phase IIb/III trials, along with preclinical candidates KSI-501 and KSI-601 [9]. Financial Performance - As of February 17, 2026, Kodiak Sciences had a market capitalization of $1.30 billion and a net income of -$217.34 million over the trailing twelve months [4]. - The company's stock price was $22.66, reflecting a 340% increase over the past year, significantly outperforming the S&P 500 [8]. Recent Developments - Braidwell LP disclosed a new position in Kodiak Sciences, acquiring 2,072,788 shares valued at $57.96 million during the fourth quarter of 2025, which represents 1.85% of Braidwell's reportable assets under management [2][8]. - Kodiak Sciences ended the third quarter with $72 million in cash and reported a quarterly net loss of $61.5 million, attributed to increased R&D spending related to active Phase 3 trials [11]. Market Context - The global anti-VEGF market, which Kodiak targets, is estimated to be around $15 billion, with three late-stage programs expected to provide topline data in 2026 [10]. - The company's strategic focus on ophthalmologists and retina specialists positions it well within a growing market for treatments of retinal vascular and inflammatory diseases [9].

Group 1 - Kiora Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 p.m. ET, with a live webcast available on their investor relations website [1] - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [2] - The company is developing KIO-104 for retinal inflammation and KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, with the latter being a molecular photoswitch aimed at restoring vision [2] Group 2 - Kiora Pharmaceuticals encourages investors to follow their updates on social media platforms like X and LinkedIn, as well as to visit their website for relevant information [3]

Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Core Insights - Kodiak Sciences' shares have increased by 24% over the past three months, driven by strong momentum from its late-stage pipeline and improved financial position, enhancing investor confidence [1] - Over the past year, Kodiak's shares have surged by 290.5%, significantly outperforming the industry's growth of 34.9% [2] Pipeline Development - Investor sentiment is positively influenced by the visibility of multiple late-stage catalysts, including the phase III GLOW2 study for tarcocimab in treatment-naïve patients with diabetic retinopathy (DR), with top-line data expected in Q1 2026 [3] - KSI-501, Kodiak's second clinical candidate, is a dual inhibitor designed to address inflammation and abnormal angiogenesis in retinal vascular diseases [4] - Tarcocimab is also being evaluated in the phase III DAYBREAK study for wet age-related macular degeneration (wet AMD), with top-line data from both investigational arms expected in Q3 2026 [5] - Kodiak has advanced KSI-101 into two pivotal phase III studies for macular edema secondary to inflammation, with top-line results anticipated in late 2026 and early 2027 [6][9] Financial Position - Kodiak Sciences has strengthened its balance sheet through an equity offering of 8.0 million shares, extending its cash runway to support operations and pipeline development [8][11] - The steady progress of its pipeline candidates has reinforced investor confidence, contributing to the stock's recent performance [10]

Core Insights - Kalaris Therapeutics, Inc. announced the presentation of clinical data from its Phase 1 study of TH103 at the 49th Annual Meeting of the Macula Society, scheduled for February 25-28, 2026, in San Diego, California [1][2] Company Overview - Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases [5] - The company was founded by Dr. Napoleone Ferrara, a pioneer in anti-VEGF therapy, and aims to advance novel therapeutic approaches for patients with sight-threatening retinal conditions [5] Product Details - TH103 is a novel investigational therapy designed to enhance VEGF inhibition and increase intraocular retention, developed by Dr. Napoleone Ferrara [2] - The upcoming presentation will cover safety, tolerability, pharmacokinetics, and early efficacy outcomes of TH103 in patients with treatment-naive neovascular age-related macular degeneration [2] Presentation Information - The presentation will be part of a scientific session attended by leading retinal specialists and clinical investigators [2][4] - The specific details of the presentation include the title "First-in-Human Evaluation of TH103, a Dual-Targeting VEGF and HSPG Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD," scheduled for February 26, 2026, at 8:15 am PT [6]

Core Insights - Kiora Pharmaceuticals reported its third quarter 2025 financial results and provided updates on its clinical pipeline for retinal diseases, highlighting the advancement of two actively enrolling Phase 2 clinical trials [1][2]. Clinical Trials Update - The company is actively recruiting participants for two Phase 2 clinical trials: ABACUS-2 for KIO-301 aimed at vision restoration in retinitis pigmentosa, and KLARITY for KIO-104 targeting retinal inflammation [2][5]. - The ABACUS-2 trial has expanded its screening and enrollment to include patients from a functional endpoint validation study, potentially increasing the patient population for KIO-301 [2][3]. - KLARITY is designed as a two-stage, multi-dose study focusing on patients with inflammatory retinal diseases causing macular edema, with a pre-defined safety assessment [3]. Financial Highlights - Kiora received $1.2 million in reimbursed R&D expenses from Théa for KIO-301 activities in Q2 2025 and billed $1.5 million in Q3 2025, with $0.3 million received in the same quarter [5][6]. - The company ended Q3 2025 with $19.4 million in cash, cash equivalents, and short-term investments, alongside $1.2 million in collaboration receivables and $1.5 million in tax and research credit receivables [5][6]. - Kiora's cash runway is projected to extend into late 2027, beyond anticipated data readouts for both clinical trials, with potential for further extension through partnership milestones [6]. R&D and Operating Expenses - R&D expenses for Q3 2025 were $2.7 million, an increase from $2.1 million in Q3 2024, primarily due to clinical trial activities [7]. - General and administrative expenses remained stable at $1.4 million for both Q3 2025 and Q3 2024 [7]. Income Statement Overview - Kiora reported a net income of $27 thousand for Q3 2025, a significant improvement from a net loss of $3.4 million in Q3 2024, attributed to favorable tax impacts and control of operating costs [8][14]. - The company recorded total revenue of $16 million for the nine months ended September 30, 2024, primarily from collaboration revenue [14]. Company Profile - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for retinal diseases using innovative small molecules [9]. - KIO-301 is being developed for retinitis pigmentosa, with plans to expand into other retinal diseases, while KIO-104 targets retinal inflammation [9].

Early Intervention with an Oral Treatment for Macular Degeneration Mission for Vision Nasdaq: BLTE B E L I T E B I O / 1 Forward-Looking Statements and Legal Disclaimer Market data and industry information used throughout this presentation are based on the knowledge of the industry and the good faith estimates of Belite Bio's management. The Company also relied, to the extent available, upon management's review of independent industry surveys and publications and other publicly available information prepare ...

Core Insights - Kiora Pharmaceuticals (KPRX) is a clinical-stage biopharmaceutical company focused on developing advanced treatments for retinal diseases [2] Drug Candidates - Kiora has two drug candidates: KIO-301 for inherited retinal diseases and KIO-104 for retinal inflammation [2][7] - KIO-301 targets surviving retinal ganglion cells to restore visual function in patients with retinitis pigmentosa [3] - KIO-104 suppresses T-cells and cytokines to reduce inflammation in the eye [7] Clinical Trials - KIO-301 is undergoing a Phase 2 clinical trial (ABACUS-2) to assess safety, tolerability, and efficacy in patients with late-stage retinitis pigmentosa, enrolling 36 patients [3][4] - KIO-104 is in a Phase 2 clinical trial (KLARITY) for retinal macular edema, with plans to enroll up to 28 patients [8][9] - Results from both clinical trials are expected in early 2027 [10] Financial Position - Kiora ended Q2 2025 with $20.7 million in cash and equivalents, plus $3.1 million in receivables and tax credits, providing a cash runway through late 2027 [11] Company Background - Kiora Pharmaceuticals was formerly known as EyeGate Pharmaceuticals Inc. and rebranded on November 8, 2021 [12] - The company's stock has traded between $2.21 and $4.18 over the past year, closing at $2.47, up 6.93% [12]